Author: [email protected]
18
October | 2022
CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy
REHOVOT, Israel and BETHESDA, Md., October 18, 2022 Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabin
29
September | 2022
CNBX Peer-reviewed Study: “Possible Future Therapeutic Value” for CNBX Proprietary Drug Candidate
REHOVOT, Israel and BETHESDA, Md., Sep 29, 2022 CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannab
28
September | 2022
CNBX Pharmaceuticals Announces New Patent Granted in Australia
TEL AVIV, Israel and BETHESDA, Md., Sep 28, 2022 REHOVOT, Israel and BETHESDA, MD., Sept. 28, 2022 - CNBX Pharmaceuticals Inc. ( OTCQB: CNBX), a glo